Psoriatic arthritis in Asia

Rheumatology

Volumn 48, Issue 12, 2009, Pages 1473-1477

  Tam, Lai Shan ^a   Leung, Ying Ying ^b   Li, Edmund K ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b NORTH DISTRICT HOSPITAL   (Hong Kong)

Author keywords

Asia; Epidemiology; Premature atherosclerosis; Psoriatic arthritis

Indexed keywords

CYTOCHROME P450 1A1; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; LYMPHOTOXIN; MANGANESE SUPEROXIDE DISMUTASE; METHOTREXATE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR INHIBITOR;

ARAB; ASIA; ATHEROSCLEROSIS; CAUCASIAN; CHINA; CHINESE; CLINICAL FEATURE; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ETHNIC DIFFERENCE; GENETIC POLYMORPHISM; GEOGRAPHY; HEREDITY; HUMAN; INCIDENCE; INDIAN; IRAN; JAPAN; LOW DRUG DOSE; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PSORIATIC ARTHRITIS; QUALITY OF LIFE; REVIEW; SEX DIFFERENCE;

ADULT; ARTHRITIS, PSORIATIC; ASIA; ATHEROSCLEROSIS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; PREVALENCE; QUALITY OF LIFE;

EID: 75749103350     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kep230     Document Type: Review

References (84)

1. Lau CS, Burgos-Vargas R, Louthrenoo W, Mok MY, Wordsworth P, Zeng QY. Features of spondyloarthritis around the world. Rheum Dis Clin North Am 1998;24: 753-70.
2. Roman MJ, Shanker BA, Davis A et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003;349:2399-406.
3. Roman MJ, Moeller E, Davis A et al. Preclinical carotid atherosclerosis in patients with rheumatoid arthritis. Ann Intern Med 2006;144:249-56.
4. O'Neill T, Silman AJ. Psoriatic arthritis. Historical background and epidemiology. Baillieres Clin Rheumatol 1994;8:245-61.
5. Alamanos Y, Voulgari PV, Drosos AA. Incidence and prevalence of psoriatic arthritis: a systematic review. J Rheumatol 2008;35:1354-8.
6. Zeng QY, Chen R, Darmawan J et al. Rheumatic diseases in China. Arthritis Res Ther 2008;10:R17.
7. Hukuda S, Minami M, Saito T et al. Spondyloarthropathies in Japan: nationwide questionnaire survey performed by the Japan Ankylosing Spondylitis Society. J Rheumatol 2001;28:554-9.
8. Thumboo J, Tham SN, Tay YK et al. Patterns of psoriatic arthritis in orientals. J Rheumatol 1997;24:1949-53.
9. Gladman DD. Psoriatic arthritis. Dermatol Ther 2009;22:40-55.
10. Jamshidi F, Bouzari N, Seirafi H, Farnaghi F, Firooz A. The prevalence of psoriatic arthritis in psoriatic patients in Tehran, Iran. Arch Iran Med 2008;11:162-5.
11. Baek HJ, Yoo CD, Shin KC et al. Spondylitis is the most common pattern of psoriatic arthritis in Korea. Rheumatol Int 2000;19:89-94.
12. Prasad PV, Bikku B, Kaviarasan PK, Senthilnathan A. A clinical study of psoriatic arthropathy. Indian J Dermatol Venereol Leprol 2007;73:166-70.
13. Fan X, Yang S, Sun LD et al. Comparison of clinical features of HLA-Cw 0602-positive and -negative psoriasis patients in a Han Chinese population. Acta Derm Venereol 2007;87:335-40.
14. Kundakci N, Tursen U, Babiker MO, Gurgey E. The evaluation of the sociodemographic and clinical features of Turkish psoriasis patients. Int J Dermatol 2002;41:220-4.
15. Kawada A, Tezuka T, Nakamizo Y et al. A survey of psoriasis patients in Japan from 1982 to 2001. J Dermatol Sci 2003;31:59-64.
16. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006;54:2665-73.
17. Pedersen OB, Svendsen AJ, Ejstrup L, Skytthe A, Junker P. The occurrence of psoriatic arthritis in Denmark. Ann Rheum Dis 2008;67:1422-6.
18. Wilson FC, Icen M, Crowson CS, McEvoy MT, Gabriel SE, Kremers HM. Time trends in epidemiology and characteristics of psoriatic arthritis over 3 decades: a population-based study. J Rheumatol 2009;36:361-7.
19. Wilson FC, Icen M, Crowson CS, McEvoy MT, Gabriel SE, Kremers HM. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study. Arthritis Rheum 2009;61:233-9.
20. Gladman DD, Anhorn KA, Schachter RK, Mervart H. HLA antigens in psoriatic arthritis. J Rheumatol 1986;13:586-92.
21. Muto M, Nagai K, Mogami S, Nakano J, Sasazuki T, Asagami C. HLA antigens in Japanese patients with psoriatic arthritis. Tissue Antigens 1995;45:362-4.
22. Liao HT, Lin KC, Chang YT et al. Human leukocyte antigen and clinical and demographic characteristics in psoriatic arthritis and psoriasis in Chinese patients. J Rheumatol 2008;35:891-5.
23. Elkayam O, Segal R, Caspi D. Human leukocyte antigen distribution in Israeli patients with psoriatic arthritis. Rheumatol Int 2004;24:93-7.
24. Rahman P, Siannis F, Butt C et al. TNFalpha polymorphisms and risk of psoriatic arthritis. Ann Rheum Dis 2006;65:919-23.
25. Hamamoto Y, Tateno H, Ishida T, Muto M. Lack of association between promoter polymorphism of the tumor necrosis factor-alpha gene and psoriatic arthritis in Japanese patients. J Invest Dermatol 2000;115:1162-4.
26. Balding J, Kane D, Livingstone W et al. Cytokine gene polymorphisms: association with psoriatic arthritis susceptibility and severity. Arthritis Rheum 2003;48:1408-13.
27. Gonzalez S, Martinez-Borra J, Torre-Alonso JC et al. The MICA-A9 triplet repeat polymorphism in the transmembrane region confers additional susceptibility to the development of psoriatic arthritis and is independent of the association of Cw*0602 in psoriasis. Arthritis Rheum 1999;42:1010-6.
28. Nelson GW, Martin MP, Gladman D, Wade J, Trowsdale J, Carrington M. Cutting edge: heterozygote advantage in autoimmune disease: hierarchy of protection/susceptibility conferred by HLA and killer Ig-like receptor combinations in psoriatic arthritis. J Immunol 2004;173:4273-6.
29. Gladman DD, Cheung C, Ng CM, Wade JA. HLA-C locus alleles in patients with psoriatic arthritis (PsA). Hum Immunol 1999;60:259-61.
30. Al-Heresh AM, Proctor J, Jones SM et al. Tumour necrosis factor-alpha polymorphism and the HLA-Cw*0602 allele in psoriatic arthritis. Rheumatology 2002;41: 525-30.
31. Chang YT, Chou CT, Yu CW et al. Cytokine gene polymorphisms in Chinese patients with psoriasis. Br J Dermatol 2007;156:899-905.
32. Lan CC, Tsai WC, Wu CS, Yu CL, Yu HS. Psoriatic patients with arthropathy show significant expression of free HLA class I heavy chains on circulating monocytes: a potential role in the pathogenesis of psoriatic arthropathy. Br J Dermatol 2004;151: 24-31.
33. Yen JH, Tsai WC, Lin CH, Ou TT, Hu CJ, Liu HW. Cytochrome p450 1Al gene polymorphisms in patients with psoriatic arthritis. Scand J Rheumatol 2004;33: 19-23.
34. Yen JH, Tsai WC, Lin CH, Ou TT, Hu CJ, Liu HW. Manganese superoxide dismutase gene polymorphisms in psoriatic arthritis. Dis Markers 2003;19:263-5.
35. Shehab DK, Al-Jarallah KF, Al-Awadhi AM, Al-Herz A, Nahar I, Haider MZ. Association of angiotensin-converting enzyme (ACE) gene insertion-deletion polymorphism with spondylarthropathies. J Biomed Sci 2008;15:61-7.
36. Al-Awadhi AM, Hasan EA, Sharma PN, Haider MZ, Al-Saeid K. Angiotensin-converting enzyme gene polymorphism in patients with psoriatic arthritis. Rheumatol Int 2007;27:1119-23.
37. Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973;3:55-78.
38. Rajendran CP, Ledge SG, Rani KP, Madhavan R. Psoriatic arthritis. J Assoc Physicians India 2003;51:1065-8.
39. Yamamoto T, Yokozeki H, Nishioka K. Clinical analysis of 21 patients with psoriasis arthropathy. J Dermatol 2005;32:84-90.
40. Tam LS, Tomlinson B, Chu TT et al. Cardiovascular risk profile of patients with psoriatic arthritis compared to controls - the role of inflammation. Rheumatology 2008;47:718-23.
41. Tsai YG, Chang DM, Kuo SY, Wang WM, Chen YC, Lai JH. Relationship between human lymphocyte antigen-B27 and clinical features of psoriatic arthritis. J Microbiol Immunol Infect 2003;36:101-4.
42. Gladman DD, Shuckett R, Russell ML, Thorne JC, Schachter RK. Psoriatic arthritis (PSA) - an analysis of 220 patients. Q J Med 1987;62:127-41.
43. Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005;64 (Suppl. 2):ii14-7.
44. Deesomchok U, Tumrasvin T. Clinical comparison of patients with ankylosing spondylitis, Reiter's syndrome and psoriatic arthritis. J Med Assoc Thai 1993;76: 61-70.
45. McHugh NJ, Balachrishnan C, Jones SM. Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology 2003;42:778-83.
46. Wright V, Moll JMH. Psoriatic arthritis. Seronegative polyarthritis. Amsterdam: North Holland Publishing, 1976:169-235.
47. Feld J, Weiss G, Rosner I et al. Electrocardiographic findings in psoriatic arthritis: a case-controlled study. J Rheumatol 2008;35:2379-82.
48. Saricaoglu H, Gullulu S, Bulbul Baskan E, Cordan J, Tunali S. Echocardiographic findings in subjects with psoriatic arthropathy. J Eur Acad Dermatol Venereol 2003; 17:414-7.
49. Gonzalez-Juanatey C, Amigo-Diaz E, Miranda-Filloy JA et al. Lack of echocardiographic and Doppler abnormalities in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Semin Arthritis Rheum 2006;35:333-9.
50. Salvarani C, Macchioni PL, Zizzi F et al. Clinical subgroups and HLA antigens in Italian patients with psoriatic arthritis. Clin Exp Rheumatol 1989;7:391-6.
51. Torre Alonso JC, Rodriguez Perez A, Arribas Castrillo JM, Ballina Garcia J, Riestra Noriega JL, Lopez Larrea C. Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients. Br J Rheumatol 1991;30:245-50.
52. Marsal S, Armadans-Gil L, Martinez M, Gallardo D, Ribera A, Lience E. Clinical, radiographic and HLA associations as markers for different patterns of psoriatic arthritis. Rheumatology 1999;38:332-7.
53. Gladman DD, Farewell VT, Nadeau C. Clinical indicators of progression in psoriatic arthritis: multivariate relative risk model. J Rheumatol 1995;22:675-9.
54. Queiro-Silva R, Torre-Alonso JC, Tinture-Eguren T, Lopez-Lagunas I. A polyarticular onset predicts erosive and deforming disease in psoriatic arthritis. Ann Rheum Dis 2003;62:68-70.
55. Gladman DD, Farewell VT, Kopciuk KA, Cook RJ. HLA markers and progression in psoriatic arthritis. J Rheumatol 1998;25:730-3.
56. Husted JA, Gladman DD, Farewell VT, Long JA, Cook RJ. Validating the SF-36 health survey questionnaire in patients with psoriatic arthritis. J Rheumatol 1997; 24:511-7.
57. Husted JA, Tom BD, Farewell VT, Schentag CT, Gladman DD. Description and prediction of physical functional disability in psoriatic arthritis: a longitudinal analysis using a Markov model approach. Arthritis Rheum 2005;53:404-9.
58. Husted JA, Gladman DD, Farewell VT, Cook RJ. Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. Arthritis Rheum 2001;45:151-8.
59. Sokoll KB, Helliwell PS. Comparison of disability and quality of life in rheumatoid and psoriatic arthritis. J Rheumatol 2001;28:1842-6.
60. Leung YY, Tam LS, Kun EW, Li EK. Impact of illness and variables associated with functional impairment in Chinese patients with psoriatic arthritis. Clin Exp Rheumatol 2008;26:820-6.
61. Ritchlin CT, Kavanaugh A, Gladman DD et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis. Advance Access published October 24, 2008, doi: ard.2008.094946.
62. Leung YY, Ho KW, Tam LS et al. Evaluation of the CASPAR criteria versus Moll and Wright criteria for psoriatic arthritis in Chinese [Abstract]. Ann Rheum Dis 2009;68 (Suppl. 3):663.
63. Howe HS, Zhao L, Song YW et al. Seronegative spondyloarthropathy - studies from the Asia Pacific region. Ann Acad Med Singapore 2007;36:135-41.
64. Lim JT, Tham SN. Methotrexate in the treatment of psoriasis at the National Skin Centre, Singapore. Ann Acad Med Singapore 1994;23:848-51.
65. Singh YN, Verma KK, Kumar A, Malaviya AN. Methotrexate in psoriatic arthritis. J Assoc Physicians India 1994;42:860-2.
66. Uthman I, Mroueh K, Arayssi T, Nasr F, Masri AF. The use of tumor necrosis factor neutralization strategies in rheumatologic disorders other than rheumatoid arthritis in Lebanon. Semin Arthritis Rheum 2004;33:422-3.
67. Koike R, Takeuchi T, Eguchi K, Miyasaka N. Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis. Mod Rheumatol 2007;17: 451-8.
68. Elkayam O, Balbir-Gurman A, Lidgi M, Rahav G, Weiler-Ravel D. [Guidelines of the Israeli association of rheumatology for the prevention of tuberculosis in patients treated with TNF-alpha blockers]. Harefuah 2007;146:235-7, 244.
69. Braun-Moscovici Y, Markovits D, Rozin A, Toledano K, Nahir AM, Balbir-Gurman A. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results. Isr Med Assoc J 2008;10: 277-81.
70. Chou CT. The clinical application of etanercept in Chinese patients with rheumatic diseases. Mod Rheumatol 2006;16:206-13.
71. Takeuchi T, Tatsuki Y, Nogami Y et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 2008;67:189-94.
72. Seong SS, Choi CB, Woo JH et al. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. J Rheumatol 2007;34:706-11.
73. Harigai M, Koike R, Miyasaka N. Pneumocystis pneumonia associated with infliximab in Japan. N Engl J Med 2007;357:1874-6.
74. Tanno M, Nakamura I, Ito K et al. Modeling and cost-effectiveness analysis of etanercept in adults with rheumatoid arthritis in Japan: a preliminary analysis. Mod Rheumatol 2006;16:77-84.
75. Wong K, Gladman DD, Husted J, Long JA, Farewell VT. Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum 1997;40:1868-72.
76. Gladman DD, Farewell VT, Wong K, Husted J. Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum 1998;41:1103-10.
77. Shbeeb M, Uramoto KM, Gibson LE, O'Fallon WM, Gabriel SE. The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991. J Rheumatol 2000;27:1247-50.
78. Kimhi O, Caspi D, Bornstein NM et al. Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis. Semin Arthritis Rheum 2007;36:203-9.
79. Han C, Robinson DW Jr, Hackett MV, Paramore LC, Fraeman KH, Bala MV. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 2006;33:2167-72.
80. Persson J, Formgren J, Israelsson B, Berglund G. Ultrasound-determined intimamedia thickness and atherosclerosis. Direct and indirect validation. Arterioscler Thromb 1994;14:261-4.
81. Gonzalez-Juanatey C, Llorca J, Amigo-Diaz E, Dierssen T, Martin J, Gonzalez-Gay MA. High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 2007;57:1074-80.
82. Eder L, Zisman D, Barzilai M et al. Subclinical atherosclerosis in psoriatic arthritis: a case-control study. J Rheumatol 2008;35:877-82.
83. Gonzalez-Gay MA, Vazquez-Rodriguez TR, Gonzalez-Juanatey C, Llorca J. Subclinical atherosclerosis in patients with psoriatic arthritis. J Rheumatol 2008;35: 2070-1.
84. Tam LS, Shang Q, Li EK et al. Subclinical carotid atherosclerosis in patients with psoriatic arthritis. Arthritis Rheum 2008;59:1322-31.